The Food and Drug Administration is evaluating the potential for airway obstruction when using silicone-based electromyogram endotracheal tubes for patient ventilation and monitoring during surgery. The agency has received reports describing serious adverse events and deaths after airway obstruction and ventilation failure using the devices, marketed in the U.S. by Medtronic. FDA is working with the manufacturer to identify potential contributing factors and mitigation strategies, and will provide an update if new information becomes available. The agency recommends health care providers follow the device’s labeling instructions; be prepared to establish a safe airway if ventilation fails; and report any adverse events or outcomes to the agency.
 

Related News Articles

Headline
The Food and Drug Administration today issued an alert on a potentially high-risk issue with Calyxo CVAC Aspiration Systems. In patients who have thick fluid…
Headline
In this conversation, Carlos Roberts, M.D., urogynecologist, vice president and chief medical officer of the Women and Children service line at WellSpan Health…
Headline
In this “Safety Speaks” conversation, CommonSpirit Health's Beth Miller, system director, patient safety-performance improvement, and Austin Peterson, system…
Headline
The Food and Drug Administration Feb. 23 withdrew approval of Pepaxto (melphalan flufenamide), a drug once used with dexamethasone to treat certain U.S.…
Headline
AHA today submitted comments on how the Agency for Healthcare Research and Quality can best support the field in advancing patient safety through an…
Headline
Abbott has recalled certain lots of its Dragonfly OpStar imaging catheter because a marker band may separate from the catheter and remain in the patient after…